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the wound surface area reduced by  1 50%, and 8/68 (12%) 
did not respond to the EpiDex treatment. Wound pain disap-
peared completely in 78% and partially in 13%. Fifteen pa-
tients (22%) received antibiotics for wound infection, and 2 
(3%) developed dermatitis (not related to the local therapy). 
Average treatment costs for venous ulcers amounted to EUR 
5,357, compared to EUR 5,722–8,622 reimbursed according 
to the German DRG system (2010) for an in-patient skin graft. 
Conclusion: EpiDex may effectively heal up to three quar-
ters of recalcitrant chronic leg ulcers. Thus, it represents an 
intermediate step to avoid costly in-patient split-skin mesh 
graft treatments. Patients remain mobilized, and a donor site 
is avoided. Large wound size or a necrotic wound bed limit 
the use of EpiDex. Otherwise, it offers the opportunity to 
avoid conventional skin grafts in a significant number of 
chronic leg ulcer patients.  Copyright © 2010 S. Karger AG, Basel 
 Background 
 Leg ulcers represent a frequent and costly medicosocial 
problem  [1–8] . They considerably impair the quality of life 
 [9–11] and usually require 3–6 months to heal in 60–80% 
of patients, with approximately 20% remaining refractory 
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 Abstract 
 Background: Approximately 20% of leg ulcers remain unre-
sponsive to the best conservative standard of care. So far, 
these patients could either receive conventional skin grafts 
or had to accept their intractable wound. Skin substitutes 
from cell culture may represent a promising alternative to 
heal a major part of these patients on a non-surgical, poten-
tially more cost-effective basis.  Objective: To systematically 
evaluate the first 68 patients treated in Switzerland (Swiss 
EpiDex  field trial 2004–2008).  Methods: Retrospective 
study on EpiDex treatment of a complete consecutive series 
of 68 patients with chronic wounds (66 chronic leg ulcers, 2 
sores) unresponsive to best conservative standard of care. 
The primary end point was complete wound closure within 
9 months after transplantation, the secondary end points 
change of wound surface area, pain reduction and overall 
judgement by the patient. Adverse effects were infection, 
dermatitis and others. Calculation of treatment costs was 
made.  Results: By the end of the study, 50/68 (74%) of pa-
tients had their wound completely healed [venous 29/37 
(78%); mixed 7/9 (78%); others 14/22 (64%)]; 10/68 (15%) had 
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EpiDex is an acronym for an autologous epidermal equivalent of
outer root sheath keratinocytes from plucked anagen hairs.
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to all conservative medical measures  [12–17] . Skin substi-
tutes derived from cell culture systems  [18] have, therefore, 
been developed and proposed for the use in the latter, dif-
ficult-to-heal leg ulcer patients, also with the goal to reduce 
the need for expensive in-patient skin grafts  [19–22] .
 Over the past 30 years, since Rheinwald and Green 
 [23] published their technique to cultivate keratinocyte 
autografts, many phase II and some phase III trials with 
cultured, autologous or allogeneic epidermal or epider-
modermal skin substitutes have been conducted all over 
the world, with the two major aims to treat extensive 
burns or chronic wounds  [18] . In Switzerland, two skin 
substitutes are commercially available for the treatment 
of difficult-to-heal leg ulcers: (a) Apligraf   [24] (Organo-
genesis, Mass., USA) and (b) EpiDex   [25] (Euroderm, 
Leipzig, Germany). Both products have proven their ef-
fectiveness in randomized controlled trials, Apligraf ver-
sus best standard of care and EpiDex versus split-skin 
grafting. Apligraf has been available in Switzerland from 
1999 to 2002, and was reintroduced in 2008. EpiDex be-
came commercially available in 2004; however, until 
2008 it was reimbursed on request only. Therefore, only 
a limited number of 68 patients were treated with this 
product during 2004–2008.
 By August 2008, Swiss regulatory authorities had ap-
proved both products for reimbursement by the common 
health insurance, provided that a chronic wound does not 
improve with the optimal standard of care for at least
3 months. The users are instructed and certified by the 
Swiss Association of Wound Care in collaboration with 
the Swiss Society of Dermatology and Venereology.
 Objective 
 The current, retrospective study was conducted to sys-
tematically evaluate effectiveness, safety, impact on 
wound pain and costs during the Swiss field trial from 
January 2004 to July 2008, including all 68 consecutive 
patients who underwent grafting of EpiDex during this 
period of time.
 Patients and Methods 
 The study was submitted to and approved by the Ethics Com-
mittee of the Canton of Zürich.
 Patients 
 The retrospective, multicentre cohort study (field study) com-
prised all 68 chronic wound patients (66 leg ulcers, 2 sores) who 
were treated in Switzerland during the period from January 2004 
to July 2008 ( table 1 ). The 7 involved centres were: Department of 
Dermatology, University Hospital of Zürich (n = 36), Regional 
Hospital Le Sentier, Vallée de Joux (n = 8), Department of Derma-
tology, University Hospital of Bern (n = 6), Department of Sur-
gery, Cantonal Hospital of Luzern (n = 3), Department of Derma-
tology, University Hospital of Basel (n = 2), Department of Der-
matology, Cantonal Hospital of St. Gallen (n = 2), Department of 
Angiology, Regional Hospital of Thun (n = 2), plus 9 wound cen-
tres or private offices each of which treated 1 patient. The com-
plete patient data sets were collected and analysed at the Depart-
ment of Dermatology at the University Hospital Zürich. Five pa-
tients had died by the end of data acquisition. In all 5 cases, the 
relatives consented to the evaluation.
 To qualify for the EpiDex procedure, patients had to present 
with a chronic leg ulcer of any main aetiology that failed to reduce 
its size for longer than 3 months despite thorough diagnosis and 
correction of all contributing factors, particularly despite ade-
quate compression treatment for chronic venous insufficiency,
saphenectomy in cases with isolated superficial venous reflux, re-
vascularization in patients with refractory mixed ulcers and an 
ankle-brachial pressure index below 0.75 or in patients with arte-
rial leg ulcers, repeated debridement of necrotic tissue and biofilm 
layers when required and systemic antibiotic treatment in cases of 
wound infection.
 Clinical Procedure 
 Negative HIV, hepatitis B and C serology is a prerequisite for 
inclusion, as required for the safety of the cell culture laboratory. 
Depending on the size of the wound, 70–350 (70/10 cm 2 wound 
surface area) anagen hairs are plucked using a forceps, mainly 
from the supra-auricular scalp. Optimally, plucking should be 
performed from Monday to Wednesday so that the outer root 
sheath keratinocytes arrive at the laboratory before Friday noon. 
The laboratory requires approximately 7–10 days to culture a 
primary keratinocyte culture and another 14–18 days to grow 
the organotypic epidermal discs of 1 cm in diameter ready for 
grafting ( fig. 1 ). Remarkably, in contrast to interfollicular kera-
tinocytes, the proliferative potential of outer root sheath kerati-
nocytes, which contain pluripotent adult stem cells, does not 
depend on the age of the donors. EpiDex is then delivered on a 
refrigerated agar soaked with transport medium in units of six 
1-cm discs, according to the wound area. The epidermal discs 
are reinforced with a silicone carrier membrane. Thursday and 
Friday are optimal days for delivery. Before application, wounds 
are cleansed once more from all necrotic tissue, fibrin layers and 
biofilms. The EpiDex discs are placed in direct contact with the 
wound, the basal cell layer facing the granulation tissue and the 
silicone membrane lying on top so that they evenly cover about 
50–70% of the wound bed ( fig. 2 a, b). The grafting procedure 
itself is painless and does not require anaesthesia. Most clini-
cians familiar with the method recommend to cover the grafted 
wound with adhesive foam ( fig. 2 c) and cotton gauze wraps. As 
an alternative, we have found a paraffin gauze covered with sa-
line-soaked sterile cotton gauze a particularly convenient dress-
ing, a technique derived from conventional surgical skin graft-
ing ( fig.  2 d). Compression treatment is applied if required to 
treat underlying venous disease or other forms of leg oedema. 
The first change of dressings is performed on days 3–5 after 
grafting. It must be conducted with the utmost care, leaving
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the silicone protective membranes untouched ( fig.  2 e), as the
EpiDex discs can easily be damaged or torn off during the initial 
phases of wound healing. Initially, the EpiDex discs may be 
barely visible, but when upon air exposure keratinization is en-
hanced with time, they become more apparent. Therefore, up to 
30 min of air drying is recommended during every change of 
dressings, which is commonly scheduled twice per week. After 
4–6 weeks, a second delivery of EpiDex is available on request, 
with the usual delay of 14–18 days to cultivate the organotypic 
secondary culture from the cryopreserved cells of the primary 
culture ( fig. 3 ).
 Evaluation of Treatment Results 
 Primary End Point. The monthly rate of completely healed 
wounds until 9 months after the first EpiDex transplantation was 
counted on an intent-to-treat base.
 Secondary End Points. Change of wound size was evaluated in 
non-healed ulcers. Patients with a wound size reduction  1 50% 
were reported as partial responders. Pain relief and overall treat-
ment satisfaction were scored by the patients using 4 quality lev-
els: 0 = no improvement or deterioration; 1 = moderate improve-
ment; 2 = marked improvement; 3 = problem resolved.
 Adverse Effects. Infection at the recipient site, increase in 
wound size, increase in pain and major discomfort during hair 
plucking were systematically recorded. Moreover, patients were 
encouraged to report any further drawbacks of the whole proce-
dure.
 Calculation of Treatment Costs 
 The calculation of treatment costs was composed by the skin 
substitute itself and medical care. The cost of EpiDex amounted 
to CHF 3,000 (EUR 2,160; USD 2,880) for small wounds (6 discs 
of 1 cm diameter), CHF 4,500 (EUR 3,240; USD 4,320) for medi-
um size wounds (9 discs of 1 cm diameter) and CHF 6000 (EUR 
4,320; USD 5,760) for larger wounds (12 discs of 1 cm diameter) 
(money exchange from August 6, 2010: 1 CHF   0.72 EUR; 1 CHF 
  0.96 USD). In 1 particular case, a wound care centre ordered 21 
discs at the cost of CHF 10,500. Monthly costs of medical care 
were calculated at CHF 600 (EUR 432; USD 576) all included, i.e. 
personnel (physicians and nurses) and material (dressings and 
bandages). Calculation of treatment costs ended with complete 
wound healing [e.g. 6 units of EpiDex and 3 months for complete 
wound closure = CHF 3,000 + 1,800 (EUR 2,175 + 1,296; USD 
2,880 + 1,728)] or at the latest at 9 months, regardless of the treat-
ment outcome.
 Results 
 Patients 
 The study included 68 patients with chronic wounds 
(66 leg ulcers, 2 sores) unresponsive to the best conserva-
tive standard of care. The median age was 75 years (mean 
70.3, SD  8 17.8, range 24–99). The female-to-male ratio 
was 35: 23. The aetiology of chronic skin ulceration is 
summarized in  table 1 . Two thirds of included patients 
(68%) had chronic venous or mixed venous-arterial ul-
cers.  The mean wound surface area was 17.0 cm 2 , SD  8 
19 cm 2 and range 1–100 cm 2 .
 Treatment Results 
 By the end of the study, 50/68 (74%) of patients had 
their wound completely healed [venous 29/37 (78%); 
mixed 7/9 (78%); others 14/22 (64%)]; 10/68 (15%) had the 
Table 1.  EpiDex Swiss Field Study 2004–2008: aetiologies of treat-
ed wounds
Aetiology Number of
patients 
treated
with EpiDex
Venous leg ulcers 37 (54%)
Mixed venous-arterial leg ulcers 9 (13%)
Martorell’s hypertensive ischaemic leg ulcer 3 (6%)
Klinefelter’s syndrome and leg ulcer 3 (6%)
Rheumatoid arthritis and venous disorder (leg) 2 (4%)
Systemic sclerosis and venous disorder (leg) 1 (2%)
Arthrogenic (stiff ankle joint) 2 (4%)
Arterial leg ulcer (non-Martorell) 2 (4%)
Adult progeria (Werner’s syndrome) 1 (2%)
Pyoderma gangraenosum under
immunosuppression (leg) 1 (2%)
Antiphospholipid syndrome (primary; foot) 1 (2%)
Livedo with summer ulceration
(non-antiphospholipid; leg) 1 (2%)
Infectious non-healing under antibiotics (leg) 1 (2%)
Postsurgical chronic wounds on the leg 1 (2%)
Dermatitis artefacta of the leg 1 (2%)
Sore in paraplegia (1 heel, 1 sacral) 2 (4%)
Total 68 (100%)
 Fig. 1. Histology of EpiDex shows the living autologous epidermal 
equivalent with its physiological stratification (basal cell layer, 
squamous cell layer, faint horn layer). 
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wound surface area reduced by  1 50% (partial response); 
8/68 (12%) did not respond to the EpiDex treatment 
( fig. 4 ).
 Complete remission of wound pain was reported by 
53/68 patients (78%). All of them had completely or al-
most completely healed wounds at the end of the study. 
In 9 patients (13%) wound pain was improved, and 1 pa-
tient (2%) did not experience any improvement of wound 
pain at all. Data on wound pain were missing in 5 pa-
tients. Overall judgement reflected largely the success in 
wound closure and pain reduction, i.e. 52 patients (76%) 
reported their problem to be completely solved, and an-
a
b
c
d
 Fig. 2.  a The EpiDex discs are placed in direct contact with the 
wound, the basal cell layer facing the granulation tissue and the 
silicone membrane lying on top.  b The discs should evenly cover 
about 50–70% of the wound bed.  c Most commonly used initial 
bandage: a thin foam.  d Alternative initial bandage: paraffin 
gauze (underlying) covered with a layer of saline-soaked sterile 
cotton wool.  e Silicone protective membranes left  in place during 
dressing changes. e
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other 6 (9%) reported substantial improvement. In total, 
58 (85%) would repeat the procedure, if necessary.
 Hair plucking caused so little discomfort as not to be 
mentioned by 52 patients (76%), and 11 (16%) felt the pain 
to be only mild (no data in 5 patients).
 Adverse Reactions 
 Wound infection was the most frequent adverse reac-
tion during the whole treatment. Fifteen patients (22%) 
received systemic antibiotic therapy for wound infection 
or critical colonization, amongst them 8 patients (12%) in 
the first week following the last EpiDex application.
 Two patients (3%) had leg eczema around their wound, 
probably due to maceration and venous stasis. Both had 
no contact to potentially allergenic dressings (exclusively 
paraffin gauze and moist cotton wool on top of EpiDex).
 Treatment Costs 
 The average treatment costs are summarized in  ta-
ble 2 .
 Discussion 
 As yet, this is the largest field trial on the use of EpiDex 
in chronic wounds, particularly hard-to-heal vascular leg 
ulcers. The results are in line with the first and only ran-
domized controlled trial of the German-Swiss study 
group  [25] . Approximately 3 in 4 leg ulcer patients can be 
healed using this innovative technique, on condition that 
the causative factors are identified and controlled and the 
wound bed is well prepared. Based on our experience,
we meanwhile suggest small- to medium-sized chronic 
a b
c d
 Fig. 3.  a Chronic venous leg ulcer at first visit (same as fig. 2a–d): dry fibrin layer and necrosis, no granulation 
tissue, no epithelization.  b Response to first EpiDex transplantation: epithelization at the top half of the wound 
area, vital granulation tissue at the bottom, second transplantation ongoing (week 8).  c After the second EpiDex 
transplantation (week 9).  d Complete epithelization (week 13). 
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wounds of any aetiology that show suitable granulation 
tissue, but lack epithelization, to be a valuable indication 
for the use of EpiDex. We acknowledge that the impressive 
results of our study have to be partially attributed to a 
positive patient selection. Very large (e.g. semicircular or 
circular leg ulcers) or totally necrotic wounds (e.g. acute 
necrotic vasculitis or Martorell hypertensive ischaemic 
leg ulcer during progressive breakdown) are unsuitable 
for this type of treatment, and such patients have not been 
treated with EpiDex during our observation period.
 Approximately 20% of chronic leg ulcers fail to heal 
under the best standard of care  [12–17] . Traditionally, 
wounds not responding to the best conservative standard 
of care either have to be accepted as intractable or to be 
Table 2.  Calculated treatment costs of the EpiDex procedure
CHF EUR USD
Venous leg ulcers (n = 37) 7,427 (4,200–14,700) 5,347 (3,024–10,584) 7,130 (4,032–14,112)
Mixed venous-arterial leg ulcers (n = 9) 10,267 (3,600–17,100) 7,392 (2,592–12,312) 9,856 (3,456–16,416)
Other leg ulcers (n = 20) and sores (n = 2) 7,391 (4,200–12,900) 5,322 (3,024–9,288) 7,095 (4,032–12,384)
All EpiDex cases (n = 68) 7,791 (3,600–17,100) 5,610 (2,592–12,312) 7,479 (3,456–16,416)
For details of calculation, see text.
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 Fig. 4. Healing rates with EpiDex, according to aetiology and overall.  a Venous ulcers: 29/37 healed (78%).
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repaired surgically, typically with a split-skin mesh graft 
 [19–22] . EpiDex as a living epidermal equivalent seems
to represent an intermediate solution. If 20/100 leg ulcer 
patients remain intractable, EpiDex may be capable to 
heal – at most – another 15 of these 20 refractory leg
ulcers. It is also noteworthy that it avoids expensive in-
patient treatment, confinement to bed and the split-skin 
donor site.
 To asses the cost-effectiveness of EpiDex in compari-
son with an in-patient split-skin graft, a variety of as-
sumptions can be made, particularly depending on the 
medical insurance models of different countries. Based 
on US reports, but also on older reports from Switzer-
land, the use of EpiDex would be half as expensive as an 
in-patient treatment [reported to amount to CHF 12,000–
18,000 (EUR 8,640–12,960; USD 11,520–17,280)] and ex-
ceptionally even more  [21, 26] . But even when the more 
rigid scale of German DRGs (diagnosis-related groups) is 
used, EpiDex would still be 6–38% more cost-effective 
than an in-patient treatment. According to the G-DRG 
Version 2010 Definition Handbook  [27] , conservative in-
patient treatment of a patient with a venous leg ulcer gets 
reimbursed with EUR 6,962.90 (DRG F21B), and surgical 
treatment of a patient with a venous ulcer of  1 4 cm 2 sur-
face by tangential ablation and mesh grafting (shave ther-
apy  [19] ) with EUR 8,621.70 (DRG F21A), calculated on 
an average base rate of EUR 2,900. The chapter for vascu-
lar diseases comprises the base DRG F21. In other cases, 
a chronic skin ulcer can also be calculated via the chapter 
for skin diseases, using the base DRG J02. In that case, 
surgical treatment of a chronic skin ulcer  1 4 cm 2 yields 
EUR 5,721.70 (DRG J02C).
 Conclusions 
 EpiDex represents a valuable autologous epidermal 
equivalent to repair hard-to-heal chronic wounds, par-
ticularly chronic vascular leg ulcers. It is capable to heal 
up to three quarters of the 20% of leg ulcer patients who 
do not respond to the best standard of conservative 
wound care. EpiDex thus offers an intermediate solution 
for these patients, to eventually avoid costly in-patient 
split-skin graft treatments. Thereby, patients always re-
main mobilized, and there is no donor site wound. Ac-
cording to the authors’ experience, EpiDex is particular-
ly suitable for small- to medium-sized chronic wounds 
that show some granulation tissue, but fail to re-epitheli-
alize.
 Hopefully, the Swiss as well as European regulatory 
authorities will abstain from submitting this type of au-
tologous keratinocyte transplantation to the criteria ap-
plied for the approval of pharmaceutical products. That 
type of reglementation must not be applied to the use of 
autologous grafting of skin cells, in which the biological 
markers and physiological functions of the cells are not 
altered or manipulated in any way. This would enable 
EpiDex to enter the European market, and then multi-
centre treatment registries could help to confirm the cur-
rently available data and to further outline the optimal 
indications. 
Disclosure Statement
Thomas Hunziker developed EpiDex and owned the original 
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